Several studies have suggested that the measurement of structurally modified albumin could assist with monitoring oxidative stress in several clinical conditions, such as renal failure, ischemic heart disease, acute appendicitis, cerebral infarction, and pre-eclampsia [19,20,21,22,23]. This evidence concerns the gene ALB and coronary artery disorder.